Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial

• Main Authors: Piero Ruggenenti, Ilian Iliev, Marco Filipponi, Stefano Tadini, Annalisa Perna, Maria Ganeva, Bogdan Ene-Iordache, Paolo Cravedi, Roberto Trevisan, Antonio Bossi, Giuseppe Remuzzi
• Format: Article
• Language: English
• Published: Hindawi Limited 2010-01-01
• Series: Journal of Ophthalmology
• Online Access: http://dx.doi.org/10.1155/2010/106384
• ISSN: 2090-004X; 2090-0058

Background. The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4–60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18–6.42), P=.0193). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy.